CN110742266B - 一种辅助调节肠道免疫功能的全营养配方食品 - Google Patents
一种辅助调节肠道免疫功能的全营养配方食品 Download PDFInfo
- Publication number
- CN110742266B CN110742266B CN201911095344.4A CN201911095344A CN110742266B CN 110742266 B CN110742266 B CN 110742266B CN 201911095344 A CN201911095344 A CN 201911095344A CN 110742266 B CN110742266 B CN 110742266B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- protein
- inflammatory bowel
- bowel disease
- soybean oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 20
- 235000013305 food Nutrition 0.000 title abstract description 31
- 230000001105 regulatory effect Effects 0.000 title abstract description 5
- 230000008944 intestinal immunity Effects 0.000 title abstract description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 235000018102 proteins Nutrition 0.000 claims description 47
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 24
- 244000061456 Solanum tuberosum Species 0.000 claims description 24
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 16
- 235000019197 fats Nutrition 0.000 claims description 16
- 235000012424 soybean oil Nutrition 0.000 claims description 14
- 239000003549 soybean oil Substances 0.000 claims description 14
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 13
- 235000019743 Choline chloride Nutrition 0.000 claims description 13
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 13
- 229960003178 choline chloride Drugs 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 12
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 235000013325 dietary fiber Nutrition 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 9
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 9
- 235000020778 linoleic acid Nutrition 0.000 claims description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 9
- 229960004488 linolenic acid Drugs 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 235000010216 calcium carbonate Nutrition 0.000 claims description 6
- 239000000395 magnesium oxide Substances 0.000 claims description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 239000011772 phylloquinone Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 235000000638 D-biotin Nutrition 0.000 claims description 4
- 239000011665 D-biotin Substances 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 229940116318 copper carbonate Drugs 0.000 claims description 4
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 4
- 229960002413 ferric citrate Drugs 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 4
- 235000006748 manganese carbonate Nutrition 0.000 claims description 4
- 239000011656 manganese carbonate Substances 0.000 claims description 4
- 229940093474 manganese carbonate Drugs 0.000 claims description 4
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 claims description 4
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- 235000021119 whey protein Nutrition 0.000 claims description 4
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- 235000021245 dietary protein Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229940050931 potassium citrate monohydrate Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000004416 zinc carbonate Nutrition 0.000 claims description 3
- 239000011667 zinc carbonate Substances 0.000 claims description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 2
- 235000006666 potassium iodate Nutrition 0.000 claims description 2
- 239000001230 potassium iodate Substances 0.000 claims description 2
- 229940093930 potassium iodate Drugs 0.000 claims description 2
- 235000015921 sodium selenite Nutrition 0.000 claims description 2
- 239000011781 sodium selenite Substances 0.000 claims description 2
- 229960001471 sodium selenite Drugs 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 5
- RSYUFYQTACJFML-DZGCQCFKSA-N afzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-DZGCQCFKSA-N 0.000 claims 1
- 239000012378 ammonium molybdate tetrahydrate Substances 0.000 claims 1
- FIXLYHHVMHXSCP-UHFFFAOYSA-H azane;dihydroxy(dioxo)molybdenum;trioxomolybdenum;tetrahydrate Chemical compound N.N.N.N.N.N.O.O.O.O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O FIXLYHHVMHXSCP-UHFFFAOYSA-H 0.000 claims 1
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 claims 1
- 210000001072 colon Anatomy 0.000 abstract description 17
- 102000003896 Myeloperoxidases Human genes 0.000 abstract description 16
- 108090000235 Myeloperoxidases Proteins 0.000 abstract description 16
- 230000000770 proinflammatory effect Effects 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 7
- 208000004232 Enteritis Diseases 0.000 abstract description 5
- 238000004904 shortening Methods 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 description 42
- 108010026552 Proteome Proteins 0.000 description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 239000003925 fat Substances 0.000 description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 description 13
- 235000010755 mineral Nutrition 0.000 description 12
- 239000011707 mineral Substances 0.000 description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 206010009887 colitis Diseases 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- 229960003975 potassium Drugs 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000465 moulding Methods 0.000 description 8
- 230000035764 nutrition Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 229930003316 Vitamin D Natural products 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 235000019166 vitamin D Nutrition 0.000 description 7
- 239000011710 vitamin D Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- 229940046008 vitamin d Drugs 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 208000002720 Malnutrition Diseases 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000014590 basal diet Nutrition 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 229930003471 Vitamin B2 Natural products 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 235000000824 malnutrition Nutrition 0.000 description 5
- 230000001071 malnutrition Effects 0.000 description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 235000019164 vitamin B2 Nutrition 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 4
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 4
- 235000019175 phylloquinone Nutrition 0.000 description 4
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 4
- 229960001898 phytomenadione Drugs 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- -1 compound vitamin Chemical class 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 229940055726 pantothenic acid Drugs 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000011713 pantothenic acid Substances 0.000 description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 229960002816 potassium chloride Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 229940100609 all-trans-retinol Drugs 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- FWBOFUGDKHMVPI-UHFFFAOYSA-K dicopper;2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O FWBOFUGDKHMVPI-UHFFFAOYSA-K 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000014872 manganese citrate Nutrition 0.000 description 1
- 239000011564 manganese citrate Substances 0.000 description 1
- 229940097206 manganese citrate Drugs 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WHOMFKWHIQZTHY-UHFFFAOYSA-L pyridoxine 5'-phosphate(2-) Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-L 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011756 sodium D-pantothenate Substances 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000019188 sodium D-pantothenate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
- 229960004267 taurolidine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种辅助调节肠道免疫功能的全营养配方食品，属于特殊医学用途配方食品领域。本发明发现炎性肠病全营养配方食品具有调节免疫从而改善炎性肠病的作用，具体体现在：(1)具有抑制肠炎小鼠结肠缩短的作用；(2)降低MPO(髓过氧化物酶)的活性；(3)具有抑制促炎因子IL‑6和TNF‑α表达的作用；(4)具有抑制促炎因子IL‑17表达的作用。因此，本发明中的配方食品在临床应用中具有巨大的应用前景。
Description
技术领域
本发明涉及一种辅助调节肠道免疫功能的全营养配方食品，属于特殊医学用途配方食品领域。
背景技术
炎性肠病简称IBD，是一种特殊的慢性肠道炎症性疾病。主要包括克罗恩病(Crohn’s disease，CD)、溃疡性结肠炎(Ulcerative Colitis，UC)。炎性肠病的病因和发病机制尚未完全明确，目前认为这是由多种因素相互作用导致的，主要包括遗传、感染、环境、免疫等因素。
临床表现：(1)消化***表现：主要包括腹痛、腹泻、脓血便、腹部包块、瘘管形成、肛周病变等。(2)多种场外表现：包括恶心、呕吐、食欲缺乏等。(3)全身表现：发热、贫血、营养不良等。
炎性肠病是常见的非传染性疾病，炎性肠病在北美洲、西欧、北欧、澳大利亚和新西兰最为常见，而且主要是在欧洲血统的白人群体中，故而被称为“西方世界的疾病”。然而，随着现代生活节奏的不断加快，由于饮食结构不合理、工作压力大，环境恶化等因素导致炎性肠病在全球发病率在迅速上升。根据国内文献报道，近5年的病例数是上世纪90年代同期的8倍，炎性肠病已逐渐成为我国消化科的常见病。
目前治疗IBD的方法包括药理学、营养学和外科。治疗的主要目的是诱导和维持缓解，纠正营养不良和预防并发症。此外，药物和外科治疗可能会损害营养素的消化和吸收，由于不同的药物-营养相互作用和手术切除后的肠道吸收面积的减少，因此极易发生营养不良。炎性肠病病人在初诊时多已伴有营养不良，而病情进展、药物或手术治疗则更加重了营养障碍，研究显示，在病情加重而住院治疗的炎性肠病患者中，蛋白质-能量营养不良发生率高达85％，约2/3的炎性肠病患者可能发生负氮平衡。由于腹泻等原因，炎性肠病患者体内血清中钾、钙、镁、磷等含量降低，一些脂溶性维生素，如维生素A、维生素E、维生素D水平也较正常人明显降低。体重丢失和低蛋白血证是炎性肠病营养不良的主要表现。因此保持良好的营养状态贯穿于炎性肠病整个治疗过程中。
对于特殊医学用途配方食品，在美国、欧盟、澳大利亚等发达国家都有相应的规定和开发应用，而我国GB29922-2013《特殊医学用途配方食品通则》食品安全国家标准中明确规定：全营养配方食品：可作为单一营养来源满足目标人群营养需求的特殊医学用途配方食品。特定全营养配方食品：可作为单一营养来源满足目标人群在特定疾病或医学状况下营养需求的特殊医学用途配方食品。
对于炎性肠病全营养配方食品，GB29922-2013《特殊医学用途配方食品通则》食品安全国家标准中明确规定：炎性肠病主要包括溃疡性结肠炎(UC)和克罗恩病(CD)。UC和CD均为肠道非特异性疾病。由于病变主要发生在消化道，既妨碍营养物质的摄入、消化、和吸收，又造成营养物质从肠道不同程度的丢失。针对上述情况，配方应使用易消化吸收的蛋白质和脂肪来源，以改善患者的营养状况和临床症状。
炎性肠病病人用全营养配方食品应满足如下技术要求：
1)可以选用整蛋白、食物蛋白质水解物、肽类和氨基酸作为蛋白质的来源。
2)脂肪供能比应不超过40％，其中中链甘油三脂(MCT)含量应不低于总脂肪的40％。
目前市面上的肠内营养制剂都是针对多种疾病状态的，相对来说，特定全营养配方更加具有针对性，比较符合当下“精准营养”的概念。而国内已获批的特医食品中还没有炎性肠病全营养配方食品。
发明内容
本发明要解决的技术问题是提供一种对肠炎常病具有营养支持作用从而改善疾病状态的配方食品，本发明严格按照国家标准，参考中国居民膳食营养素参考摄入量，设计符合国内人群的配方。同时选用多种有益成分，以乳基蛋白、马铃薯蛋白、MCT、麦芽糊精、益生元为主要原料，辅以复合矿物质。复合维生素，可作为单一营养来源满足炎性肠病患者的需求。
本发明的第一个目的是提供一种炎症肠病全营养配方食品，每100千卡食品包括如下成分：蛋白质、碳水化合物、脂肪、膳食纤维、复合维生素、复合矿物质、营养强化剂；按供能比计，所述蛋白质供能15％-20％；所述脂肪供能20％-30％；所述碳水化合物供能50％-65％；所述蛋白质为乳清蛋白、酪蛋白和马铃薯蛋白的混合蛋白；所述脂肪中中链甘油三脂占总脂肪含量≥40％，亚油酸提供的能量≥2.0％(以配方整体计)，α-亚麻酸提供的能量≥0.5％(以配方整体计)；所述膳食纤维≥2.7g，所述复合维生素≥6.2mg，所述复合矿物质≥527.6mg，所述营养强化剂为22.2-166.7mg。
在一种实施方式中，所述混合蛋白中乳清蛋白：酪蛋白：马铃薯蛋白＝1：1：1。
在一种实施方式中，所述矿物质包括钠元素、钾元素、钙元素、镁元素、铁元素、锌元素、硒元素、锰元素、铜元素、磷元素、碘元素、铬元素和钼元素。
在一种实施方式中，所述矿物质包括如下成分：钠元素至少83mg、钾元素至少111mg、铜元素44-500μg、镁元素18.3mg、铁元素0.83-2.30mg、锌元素0.4-2.2mg、锰元素25-611μg、钙元素至少56mg、磷元素至少40mg、碘元素至少6.7μg、氯元素至多218mg、硒元素3.3-22.2μg、铬1.8-55.6μg、钼5.6-50μg。
在一种实施方式中，所述钠元素的来源选自氯化钠、磷酸二氢钠、磷酸氢二钠、柠檬酸钠、碳酸氢钠中的一种或一种以上；所述钾元素的来源选自磷酸二氢钾、磷酸氢二钾、葡萄糖酸钾、柠檬酸钾、氯化钾中的一种或一种以上；所述铜元素的来源选自硫酸铜、柠檬酸铜、葡萄糖酸铜、碳酸铜中的一种或一种以上；所述镁元素的来源选自硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁、葡萄糖酸镁中的一种或一种以上；所述铁元素的来源选自焦磷酸铁、硫酸亚铁、葡萄糖酸亚铁、富马酸亚铁、乙二胺四乙酸铁钠、柠檬酸铁、柠檬酸铁铵中的一种或一种以上；所述锌元素的来源选自硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、氯化锌、乙酸锌、柠檬酸锌中的一种或一种以上；所述锰元素的来源选自硫酸锰、氯化锰、碳酸锰、柠檬酸锰、葡萄糖酸锰中的一种或一种以上；所述钙元素的来源选自碳酸钙、葡萄糖酸钙、柠檬酸钙、L-乳酸钙、磷酸氢钙、氯化钙、甘油磷酸钙、磷酸三钙、氧化钙、硫酸钙中的一种或一种以上；所述磷元素的来源选自磷酸钙、磷酸氢钙中的一种或一种以上；所述碘元素的来源选自碘化钾、碘酸钾、碘化钠中的一种或一种以上；所述氯元素的来源选自氯化钾、氯化钠、氯化锰、氯化锌、氯化镁、氯化胆碱中的一种或一种以上；所述硒元素的来源选自***钠、硒酸钠中的一种或一种以上；所述铬元素的来源选自硫酸铬、氯化铬中的一种或一种以上；所述钼元素的来源选自钼酸钠、钼酸铵中的一种或一种以上。
在一种实施方式中，所述维生素包括维生素A、维生素D、维生素E、维生素K、维生素C和B族维生素。
在一种实施方式中，所述维生素包括如下成分：维生素A 39-225μg、维生素D 0.8-3.14μg、维生素E至少0.8mg、维生素K1至少4.4μg、维生素B1至少0.07mg、维生素B2至少0.07mg、维生素B6至少0.07mg、维生素B12至少0.13μg、维生素C至少5.6mg、烟酸至少0.2mg、叶酸至少22.2μg、泛酸至少0.29mg、生物素至少2.2μg。
在一种实施方式中，所述维生素A的来源选自醋酸视黄脂、棕榈酸视黄酯、全反式视黄醇、β-胡萝卜素中任意一种或一种以上；所述维生素D的来源选自麦角钙化醇、胆钙化醇中的一种或一种以上；所述维生素E的来源选自d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚、dl-α-醋酸生育酚、混合生育酚浓缩物、d-α-琥珀酸生育酚、dl-α-琥珀酸生育酚中的一种或一种以上；所述维生素K1的来源为植物甲萘醌；所述维生素B1的来源选自盐酸硫胺素、硝酸硫胺素中的一种或一种以上；所述维生素B2的来源选自核黄素、核黄素-5’-磷酸钠中的一种或一种以上；所述维生素B6的来源选自盐酸吡哆醇、5’-磷酸吡哆醇中的一种或一种以上；所述维生素B12的来源选自氰钴胺、盐酸氰钴胺、羟钴胺中的一种或一种以上；所述维生素C的来源选自L-抗坏血酸、L-抗坏血酸钾、L-抗坏血酸钠、L-抗坏血酸钙、抗坏血酸-6-棕榈酸盐中的一种或一种以上；所述烟酸的来源选自烟酸、烟酰胺中的一种或一种以上；
在一种实施方式中，所述泛酸的来源选自D-泛酸钠、D-泛酸钙中的一种或一种以上。
在一种实施方式中，所述生物素为D-生物素。
在一种实施方式中，所述营养强化剂包括牛黄碱、左旋肉碱、肌醇和胆碱中的一种或一种以上。
在一种实施方式中，所述胆碱选自酒石酸氢胆碱、氯化胆碱中的一种或一种以上。
本发明的第二个目的是提供含有上述任一所述食品的产品。
本一种实施方式中，所述产品的剂型包含粉剂、颗粒或口服液。
本发明提供的所述炎症肠病全营养配方食品的制备方法，该方法包括如下步骤：
(1)称量各原料，并粉碎；
(2)将大豆油、MCT混合，优选过30-50目筛，进一步优选过40目筛，备用；
(3)将麦芽糊精、膳食纤维、蛋白质混合，优选过30-50目筛，进一步优选过40目筛，备用；
(4)将剩余的复合矿物质，复合维生素、牛磺酸、胆碱混合，优选过30-50目筛，进一步优选过40目筛，备用；
(5)将上诉步骤(2)、(3)、(4)得到的物料混合均匀；
(6)将步骤(5)得到的物料混合为粉剂，进一步制成颗粒或者口服液。
本发明还要求保护上述任一所述食品在制备辅助调节肠道免疫功能的食品或产品中的应用。
有益效果：本发明的炎性肠病全营养配方食品可以调节免疫从而改善炎性肠病，具体体现在：
(1)具有抑制肠炎小鼠结肠缩短的作用，可使小鼠结肠长度由4.86cm增长到5.33～5.5cm；
(2)降低MPO(髓过氧化物酶)的活性，可使MPO由6.83pg/mg降到5.12pg/mg；
(3)具有抑制组织中促炎因子IL-6，TNF-α产生的作用，能够使TNF-α由44.55pg/mgprotein降到28.98pg/mg protein，使IL-6由52.03pg/mg protein降低至34.97pg/mgprotein；
(4)抑制组织中促炎因子IL-17产生的作用，能够使促炎因子IL-17由34.18pg/mg降低到21.23pg/mg。
附图说明
图1是炎性肠病营养配方食品改善结肠缩短的作用；
图2是炎性肠病营养配方食品降低MPO(髓过氧化物酶)的活性；
图3是炎性肠病营养配方食品抑制促炎因子IL-6和TNF-α的表达；
图4是炎性肠病营养配方食品抑制促炎因子IL-17的表达。a，b表示不同字母所代表的组别存在显著性的差异(P<0.05)。
具体实施方式
中链甘油三酯(MCT)仅由饱和脂肪酸构成，凝固点低，室温下为液体，粘度小。与大豆油比较，完全是无臭、无色的透明液体。与普通的油脂和氢化油脂相比，中链甘油三酷中不饱和脂肪酸的含量极低，氧化稳定性非常好，其碘值不超过0.5。故在高温和低温下特别稳定。中链甘油三酷具有良好的溶解性以及能被快速吸收，在20世纪50年代已经被证明对吸收不良综合征的饮食治疗具有临床价值，通常在许多临床营养环境中用作特殊能量来源。
麦芽糊精是以各类淀粉作原料，经酶法工艺低程度控制水解转化，提纯，干燥而成。其原料是含淀粉质的玉米，大米等。具有甜度低，溶解性好，不易吸潮，稳定性好，难以变质的特性。具有增稠性强，载体性好，发酵性小，填充效果好，不吸潮、无异味、易消化、低热、低甜度等特点。麦芽糊精含有大量的多糖类，另外还含有钙、铁等对人体有益的微量元素及矿物质，并能促进人体正常的物质代谢。被广泛应用于食品、保健品、医药生产中。
益生元：它是一种膳食补充剂，食物经消化吸收后到达结肠，在肠道腐生菌(大肠杆菌、拟杆菌等)的作用下，可产生许多有毒的代谢产物(如氨、亚硝胺、苯酚与甲苯酚、次级胆汁酸等)，而益生元在结肠被发酵产生的短链脂肪酸能够降低结肠pH，抑制腐生菌的生长，减少有毒产物的生成，减少其对肠壁的刺激，有助于改善和维持肠道正常功能长期食用可以延缓衰老、通便、提高免疫力、减轻肝脏负担、提高营养素的吸收率，特别是能够改善机体对钙、铁、锌等金属离子的吸收可选择性地促进有益菌双歧、乳酸的生长繁殖，本发明选用的菊粉是不易消化的植物成分，主要是低聚糖，是一种可溶性膳食纤维，可延长肠传递时间，且由于吸水能力强，可改善腹泻等症状，已广范应用于炎性肠病的治疗。
维生素和矿物质：维生素和矿物质是人体必需的营养素，本发明中添加的维生素为维生素和矿物质是人体必需的营养素。本发明中添加的维生素为维生素A、维生素D、维生素E、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、烟酸、叶酸、泛酸、胆碱的混合物。本发明中添加的矿物质为钾、钠、钙、镁、氯、磷、铁、锌、硒、锰、铜、碘、铬、钼的混合物，本发明所述的维生素和矿物质添加为其有机或无机化合物。参照GB14880-2012《食品营养强化剂使用标准》、本发明中维生素和矿物质的添加量参GB29922-2013《食品营养强化剂使用卫生标准》执行。
实施例1：含有混合蛋白的营养配方设计
按照下述配方制备营养配方食品，每100g含有：碳水化合物(麦芽糊精)60g、蛋白质18g、脂肪12g、膳食纤维4g、维生素A 669.6IU、维生素D 3.125μg、维生素E 0.0056IU、维生素K1 0.024mg、维生素B1 1.025mg、维生素B2 1.025mg、维生素B6 1.25mg、维生素B120.003mg、维生素C 85.78mg、烟酸9.125mg、叶酸0.12mg、泛酸钙5.71mg、D-生物素0.01mg、氯化钠953.23mg、一水柠檬酸钾217.92mg、碳酸铜1.388mg、氧化镁247.016mg、柠檬酸铁43.424mg、碳酸锌10.304mg、碳酸锰3.48mg、碳酸钙1005.1mg、磷酸二氢钾1466.39mg、碘酸钾0.089mg、***钠0.061mg、硫酸铬钾0.324mg、四水钼酸铵0.094mg、氯化胆碱167.56mg。其中，碳水化合物为麦芽糊精，蛋白质为植物蛋白与乳类蛋白的混合物，乳清蛋白：酪蛋白：马铃薯蛋白＝1：1：1。脂肪中按质量比计，大豆油：MCT为1:1，其中大豆油中含有亚油酸和α-亚麻酸，亚油酸占大豆油质量的52％，亚麻酸占大豆油质量的7％；膳食纤维为菊粉。
本实施例制备的全营养食品，每100千卡包括提供58千卡能量的碳水化合物、提供17千卡能量的蛋白质、提供25千卡能量的脂肪，所述脂肪中中链甘油三脂占总脂肪含量的50％，亚油酸提供的能量为6.5％，α-亚麻酸提供的能量为0.88％。
实施例2：马铃薯蛋白组
按照下述配方制备营养配方食品，每100g含有：碳水化合物(麦芽糊精)60g、蛋白质18g、脂肪12g、膳食纤维4g、维生素A 669.6IU、维生素D 3.125μg、维生素E 0.0056IU、维生素K1 0.024mg、维生素B1 1.025mg、维生素B2 1.025mg、维生素B6 1.25mg、维生素B120.003mg、维生素C 85.78mg、烟酸9.125mg、叶酸0.12mg、泛酸钙5.71mg、D-生物素0.01mg、氯化钠953.23mg、一水柠檬酸钾217.92mg、碳酸铜1.388mg、氧化镁247.016mg、柠檬酸铁43.424mg、碳酸锌10.304mg、碳酸锰3.48mg、碳酸钙1005.1mg、磷酸二氢钾1466.39mg、碘酸钾0.089mg、***钠0.061mg、硫酸铬钾0.324mg、四水钼酸铵0.094mg、氯化胆碱167.56mg。
其中，蛋白质为马铃薯蛋白；碳水化合物为麦芽糊精；脂肪中按质量比计，大豆油：MCT为1:1，其中大豆油中含有亚油酸和α-亚麻酸，亚油酸占52％，α-亚麻酸占7％；膳食纤维为菊粉。
本实施例制备的全营养配方食品，每100千卡包括提供58千卡能量的碳水化合物、提供17千卡能量的蛋白质、提供25千卡能量的脂肪，所述脂肪中中链甘油三脂占总脂肪含量的50％，亚油酸提供的能量为6.5％，α-亚麻酸提供的能量为0.88％。
实施例3炎性肠病全营养配方食品抑制肠炎小鼠结肠缩短
将6-8周SPF级18-20g健康雄性C57BL/6小鼠40只随机分为4组：空白组(喂食基础饲料)、模型组(喂食基础饲料)、混合蛋白组(喂食实施例1的营养配方食品)、马铃薯蛋白组(喂食实施例2的营养配方食品)。每组10只，饲养在江南大学实验动物中心，恒定温度21-26℃，湿度40-70％，噪声小于等于60dB，动物照度15-20LX。所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准。
实验第1天到第7天在小鼠的饮水中中添加3.5％DSS诱发急性结肠炎，饮用3个周期(每个周期7天的DSS处理，14天的自由饮水，循环3次)，以诱发慢性结肠炎。造模期间空白组正常饮水，喂食基础饲料；造模成功后模型组处死；之后混合蛋白组、马铃薯蛋白组正常饮水，饮食改为营养配方，混合蛋白组喂食实施例1制备的营养配方、马铃薯蛋白组喂食实施例2制备的营养配方。第15天(D15)实验结束后取血并处死小鼠。解剖腹腔，取出小鼠结肠，并量长记录。
肠炎伴随着结肠长度缩短，因此，结肠长度可以很好地反映疾病状况。这些结果如附图1所示，与模型组相比，本发明中混合蛋白组、马铃薯蛋白组在实验后的结肠长度明显增长，分别由4.86cm增长到5.33cm、5.5cm，表明对结肠炎症状的有效改善。
实施例4炎性肠病全营养配方食品降低MPO(髓过氧化物酶)的活性实验
将6-8周SPF级18-20g健康雄性C57BL/6小鼠40只随机分为4组：空白组(喂食基础饲料)、模型组(喂食基础饲料)、混合蛋白组(喂食实施例1的营养配方食品)、马铃薯蛋白组(喂食实施例2的营养配方食品)。每组10只，饲养在江南大学实验动物中心，恒定温度21-26℃，湿度40-70％，噪声小于等于60dB，动物照度15-20LX。所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准。
实验第1天到第7天在水壶中添加3.5％DSS诱发急性结肠炎，饮用3个周期(每个周期7天的DSS处理，14天的自由饮水，循环3次)，以诱发慢性结肠炎。造模期间空白组正常饮水，喂食基础饲料；造模成功后模型组处死；之后混合蛋白组、马铃薯蛋白组正常饮水，饮食改为营养配方，混合蛋白组喂食实施例1制备的营养配方、马铃薯蛋白组喂食实施例2制备的营养配方。第15天(D15)实验结束后取血并处死小鼠。
取小鼠同一位置结肠组织的匀浆液，通过MPO试剂盒进行MPO活性测定。小鼠结肠髓过氧化物酶(MPO)活性反应结肠组织中性粒细胞浸润程度，故MPO值可表征炎症程度，若MPO活性越强，则炎症越严重。
这些结果如图2所示。由图2可知，本发明中，相对于模型组，混合蛋白组、马铃薯蛋白组在实验后MPO值有显著的下降，分别由6.83pg/mg protein降到了5.12pg/mg protein、5.23pg/mg protein。与空白组无显著差异。表明实施例1或2的配方可以减轻结肠炎小鼠的炎症状态。
实施例5炎性肠病全营养配方食品调节Th1通路抑制促炎因子TNF-α、IL-6表达的实验
将6-8周SPF级18-20g健康雄性C57BL/6小鼠40只随机分为4组：空白组、模型组、营养配方组一(混合蛋白组)、营养配方组二(马铃薯蛋白组)。每组10只，饲养在江南大学实验动物中心，恒定温度21-26℃，湿度40-70％，噪声小于等于60dB，动物照度15-20LX。所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准。
实验第1天到第7天在水壶中添加3.5％DSS诱发急性结肠炎，饮用3个周期(每个周期7天的DSS处理，14天的自由饮水，循环3次)，以诱发慢性结肠炎。造模期间空白组正常饮水，喂食基础饲料；造模成功后模型组处死；之后混合蛋白组、马铃薯蛋白组正常饮水，饮食改为营养配方，混合蛋白组喂食实施例1制备的营养配方、马铃薯蛋白组喂食实施例2制备的营养配方。第15天(D15)实验结束后取血并处死小鼠。
取小鼠同一位置结肠组织进行组织匀浆，之后通过ELISA试剂盒测定炎症因子。
这些结果如图3所示，与模型组相比，本发明中混合蛋白组中的促炎因子TNF-α、IL-6均出现显著降低，与空白组无显著差异，分别由44.55pg/mg protein降到了28.98pg/mg protein，52.03pg/mg protein降低至34.97pg/mg protein。而马铃薯蛋白组与模型组没有显著差异，表明本发明中的配方，能够抑制Th1反应，它显著下调肠炎典型上调Th1相关的细胞因子至正常水平，促进了结肠免疫的平衡，具有抗炎作用。
实施例6炎性肠病全营养配方食品调节Th17通路抑制促炎因子IL-17表达的实验
将6-8周SPF级18-20g健康雄性C57BL/6小鼠40只随机分为4组：(喂食基础饲料)、模型组(喂食基础饲料)、混合蛋白组(喂食实施例1的营养配方食品)、马铃薯蛋白组(喂食实施例2的营养配方食品)。每组10只，饲养在江南大学实验动物中心，恒定温度21-26℃，湿度40-70％，噪声小于等于60dB，动物照度15-20LX。所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准。
实验第1天到第7天在水壶中添加3.5％DSS诱发急性结肠炎，饮用3个周期(每个周期7天的DSS处理，14天的自由饮水，循环3次)，以诱发慢性结肠炎。造模期间空白组正常饮水，喂食基础饲料；造模成功后模型组处死；之后混合蛋白组、马铃薯蛋白组正常饮水，饮食改为营养配方，混合蛋白组喂食实施例1制备的营养配方、马铃薯蛋白组喂食实施例2制备的营养配方。第15天(D15)实验结束后取血并处死小鼠。
取小鼠同一位置结肠组织进行组织匀浆，之后通过ELISA试剂盒测定炎症因子。
这些结果如附图4所示，与模型组相比，本发明中混合蛋白组中的促炎因子IL-17出现显著降低，与空白组无显著差异，由34.18pg/mg protein降低到了21.23pg/mgprotein。而马铃薯蛋白组与模型组没有显著差异，表明本发明中的配方，能够抑制Th17反应，它显著下调肠炎典型上调Th17相关的细胞因子至正常水平，而马铃薯蛋白组不具备这个作用。
虽然本发明已以较佳实施例公开如上，但其并非用以限定本发明，任何熟悉此技术的人，在不脱离本发明的精神和范围内，都可做各种的改动与修饰，因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (3)
1.一种炎症肠病全营养制剂，其特征在于，每100g含有：麦芽糊精 60 g、蛋白质18g、脂肪12g、膳食纤维4g、维生素A 669.6IU、维生素D 3.125μg、维生素E 0.0056IU、维生素K10.024mg、维生素B1 1.025mg、维生素B2 1.025mg、维生素B6 1.25mg、维生素B12 0.003mg、维生素C 85.78mg、烟酸9.125mg、叶酸0.12mg、泛酸钙5.71mg、D-生物素0.01mg、氯化钠953.23mg、一水柠檬酸钾217.92mg、碳酸铜1.388mg、氧化镁247.016mg、柠檬酸铁43.424mg、碳酸锌10.304mg、碳酸锰3.48mg、碳酸钙1005.1mg、磷酸二氢钾1466.39mg、碘酸钾0.089mg、***钠0.061mg、硫酸铬钾0.324mg、四水钼酸铵0.094mg、氯化胆碱167.56mg；所述蛋白质为混合蛋白，所述混合蛋白中乳清蛋白：酪蛋白：马铃薯蛋白=1：1：1；所述脂肪由大豆油和中链甘油三脂组成，按质量比计，大豆油：中链甘油三脂为1:1，其中大豆油中含有亚油酸和α-亚麻酸，亚油酸占大豆油质量的52%，亚麻酸占大豆油质量的7%；所述膳食纤维为菊粉。
2.根据权利要求1所述的炎症肠病全营养制剂，其特征在于，所述炎症肠病全营养制剂为粉剂、颗粒或口服液。
3.一种制备权利要求1或2所述炎症肠病全营养制剂的方法，其特征在于，包括如下步骤：
（1）称量各原料，并粉碎；
（2）将大豆油、中链甘油三脂混合，过筛；
（3）将麦芽糊精、膳食纤维、蛋白质混合，过筛；
（4）将剩余的原料混合，过筛；
（5）将步骤（2）、（3）、（4）得到的物料混合均匀，或将步骤（2）、（3）、（4）得到的物料混合均匀后得到的混合物料进一步制成颗粒或者口服液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911095344.4A CN110742266B (zh) | 2019-11-11 | 2019-11-11 | 一种辅助调节肠道免疫功能的全营养配方食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911095344.4A CN110742266B (zh) | 2019-11-11 | 2019-11-11 | 一种辅助调节肠道免疫功能的全营养配方食品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110742266A CN110742266A (zh) | 2020-02-04 |
| CN110742266B true CN110742266B (zh) | 2022-11-01 |
Family
ID=69282871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911095344.4A Active CN110742266B (zh) | 2019-11-11 | 2019-11-11 | 一种辅助调节肠道免疫功能的全营养配方食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110742266B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111938144B (zh) * | 2020-07-13 | 2021-09-24 | 浙江大学 | 一种半流体顺滑质构无渣全营养食品及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1429113A (zh) * | 2000-05-08 | 2003-07-09 | 努特里奇亚有限公司 | 包含核糖和叶酸的营养制剂及其药用 |
| CN103458888A (zh) * | 2011-04-12 | 2013-12-18 | 雀巢产品技术援助有限公司 | 用于改善肠屏障功能的包含支链脂肪酸的营养组合物 |
| CN105747218A (zh) * | 2010-06-28 | 2016-07-13 | 雀巢产品技术援助有限公司 | 低热量、高蛋白质营养组合物及其应用方法 |
| CN106983151A (zh) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | 一种炎性肠病专用型临床营养配方及其制备方法 |
| CN109998120A (zh) * | 2019-04-15 | 2019-07-12 | 四川婷杰健康产业有限责任公司 | 一种高饱腹感营养代餐食品及其制备方法 |
-
2019
- 2019-11-11 CN CN201911095344.4A patent/CN110742266B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1429113A (zh) * | 2000-05-08 | 2003-07-09 | 努特里奇亚有限公司 | 包含核糖和叶酸的营养制剂及其药用 |
| CN105747218A (zh) * | 2010-06-28 | 2016-07-13 | 雀巢产品技术援助有限公司 | 低热量、高蛋白质营养组合物及其应用方法 |
| CN103458888A (zh) * | 2011-04-12 | 2013-12-18 | 雀巢产品技术援助有限公司 | 用于改善肠屏障功能的包含支链脂肪酸的营养组合物 |
| CN106983151A (zh) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | 一种炎性肠病专用型临床营养配方及其制备方法 |
| CN109998120A (zh) * | 2019-04-15 | 2019-07-12 | 四川婷杰健康产业有限责任公司 | 一种高饱腹感营养代餐食品及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110742266A (zh) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Type I glycogen storage disease: nine years of management with cornstarch | |
| CN110742267B (zh) | 一种炎性肠病全营养配方食品 | |
| KR101577083B1 (ko) | 골다공증을 예방 및 개선하기 위한 칼슘, 마그네슘, 아연, 및 비타민 ｄ3을 포함하는 배합물 | |
| CN110638043A (zh) | 一种富含益生菌的全营养配方食品及其制备方法与应用 | |
| CN108719977A (zh) | 一种乳腺癌营养食品及其制备方法 | |
| CN110638042A (zh) | 一种全营养配方食品及其应用 | |
| JPS58501676A (ja) | 微量物質としてセレニウムをヒトに供給するための混合物、ならびに細胞培養のための培地中に器官を保存する溶液および血液成分を保存する栄養溶液におけるその使用 | |
| CN110742266B (zh) | 一种辅助调节肠道免疫功能的全营养配方食品 | |
| WO2005115472A2 (en) | Compositions comprising gamma-linolenic acid and iodine for improving breast health in women | |
| CN107467193A (zh) | 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法 | |
| KR20080008155A (ko) | 한국인에게 특별히 필요한 비타민, 무기질, 또는 발효시킨천연물을 함유하는 영양제 조성물 | |
| CN108851037A (zh) | 一种肾病综合征全营养食品的制备方法及其用途 | |
| EP3091975B1 (en) | Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring | |
| AU2012288401B9 (en) | Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis | |
| Craig et al. | 10 Critical Nutrients in | |
| Jackson et al. | Nutritional requirements of infants and children | |
| KR20220019270A (ko) | 만성 염증성 장 질환을 앓고 있는 개체에서 영양실조의 예방 또는 치료 방법에 사용하기 위한 조성물 | |
| Strachan et al. | Selenium in critically ill patients | |
| CN108902933A (zh) | ***癌全营养食品及其制备方法 | |
| CN108782764A (zh) | 预防结肠炎的婴幼儿奶粉及其制备方法 | |
| CN113615832B (zh) | 一种适用于高脂血症型急性胰腺炎患者恢复期的组合物及其制备方法 | |
| Amirli et al. | THE ROLE OF NUTRITION IN ENSURING HEALTHY LIVING | |
| Hanson | Calcium supplements-an overview | |
| CN111631404A (zh) | 药食兼用复合维生素微量元素棕榈油亚麻油营养油及制造方法 | |
| NUTA et al. | Victoria-Madalina MIHAESCU", Raluca-Ioana DASCALU" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |